ArticleImmunity, inflammation and disease2026
Ginkgolide B Alleviates Airway Inflammation in Hyperoxia Lung Injury.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchopulmonary dysplasia (BPD) is a chronic lung disease characterized by inflammation, often caused by prolonged hyperoxia exposure in preterm infants. Platelet-activating factor (PAF) is a potent inflammatory mediator, but its role in BPD is unclear. This study explores the therapeutic potential of the PAF receptor antagonist Ginkgolide B (GB) in hyperoxia-induced lung injury.
methodsWe observed the activation status of platelets and neutrophils in BALF（bronchoalveolar lavage fluid) of patients with BPD. The supernatant of BALF from patients was sent for protein chip detection and validated by ELISA. We also measured the levels of PAF in peripheral blood and BALF. In vitro experiments, we stimulated neutrophils with PAF to detect the expression of inflammatory cytokine genes. Finally, we established a neonatal rat model of hyperoxia-induced lung injury mimicking BPD and intervened with GB.
resultsWe observed early activation of platelets and neutrophils in the peripheral blood of BPD patients, with elevated plasma levels of PAF and myeloperoxidase-DNA (MPO-DNA). In BALF, neutrophils showed increased CD66b and MPO expression. In vitro, PAF stimulation decreased CD62L expression on neutrophils and upregulated IL-6 mRNA. Elevated levels of PAF, IL-6, IL-8, and GM-CSF were found in BPD infants' BALF supernatant. Using animal models of BPD, we found that GB significantly reduced lung damage in hyperoxia-exposed rats. GB decreased neutrophil-derived IL-6 and downregulated key proteins in the IL-6 signaling pathway (pJak2 and pStat3).
conclusionOur study demonstrates that PAF activates neutrophils and promotes their lung residence. GB effectively inhibits neutrophil-derived IL-6 and alleviates hyperoxia-induced lung damage. Targeting the PAF pathway with GB may be a promising strategy for BPD and other hyperoxia-related lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.